Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III study of Prochymal for steroid-refractory acute graft-versus-host disease
2006-004420-37Phase 3Completed
- Sponsor
- Osiris Therapeutics, Inc.
- Start
- Jun 2007
- Modality
- Stem Cell Therapies → Cell Therapies
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in Acute Graft-Versus-Host Disease (aGvHD) comparing Prochymal with Placebo (2 arms). Primary endpoint: Complete response of at least 28 days duration. Started Jun 2007; status: completed.
02
Drugs
remestemcel-L-rknd
03
Conditions
Acute Graft-Versus-Host Disease (aGvHD)
Beyond the preview
Go deeper on 2006-004420-37.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-004420-37.